Physician profile
Adelbert Evangelista
NPI 1629018619
$1,995.80
in general payments reported to CMS, 2019-2025
27 companies · $26.07 in 2025
The $26.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $306 · 2021: $692 · 2022: $437 · 2023: $237 · 2024: $103 · 2025: $26.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.84 | 2021-2023 | |
| Amgen INC. | $335.01 | 2020-2023 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $188.15 | 2020-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $154.61 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $123.92 | 2020-2021 | |
| Exact Sciences Corporation | $83.64 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $78.28 | 2019-2021 | |
| Lucid Diagnostics INC. | $59.08 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $55.31 | 2021 | |
| Astellas Pharma US INC | $54.05 | 2021-2024 | Veozah |
| Allergan, INC. | $49.71 | 2020 | |
| Glaxosmithkline, LLC. | $46.89 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $31.24 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.44 | 2023 | |
| Viatris Specialty LLC | $26.07 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $25.86 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $24.82 | 2021-2022 | |
| Lilly USA, LLC | $23.47 | 2019-2020 | |
| Abbott Laboratories | $23.27 | 2024 | Eterna |
| Biohaven Pharmaceutical Holding Company LTD. | $22.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2022 | |
| Biogen, INC. | $17.21 | 2021 | |
| Advanced Respiratory, INC | $17.15 | 2021 | |
| Amarin Pharma, INC. | $11.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelbert Evangelista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.